Moderna’s first data drop for its Covid-19 vaccine, mRNA-1273, was criticised for not including older subjects – the ones who need protection from coronavirus the most. But results released today from the same phase I NIAID-sponsored trial show promise in older age groups. A 100µg dose of mRNA-1273, which Moderna is taking into phase III, elicited encouraging levels of neutralising antibodies in older people. These antibodies are a proxy for vaccine efficacy; as older people have weaker immune systems, there had been concerns that they would not respond to Covid-19 vaccines as well as younger people. There had also been worries about side-effects in the older population, but the adverse-event profile of the 100µg dose in those aged over 55 does not look too burdensome, the CDC’s Advisory Committee on Immunization Practices heard today. Moderna, whose stock rose 6% this morning, still has much to prove – not least that a neutralising antibody response translates into protection against Covid-19. Interestingly, 25-40% of the group’s phase III trial subjects will be either over 65 or at increased risk of complications of Covid-19. The study had enrolled over 13,000 patients as of Friday.
Source: Company presentation
Source: Company presentation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.